Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 15;25(6):1310-7.
doi: 10.1016/j.bmcl.2015.01.038. Epub 2015 Jan 28.

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

Affiliations

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

María Luz Martín-Martín et al. Bioorg Med Chem Lett. .

Abstract

We report the discovery and SAR of two novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs). Exploration of several structural features in the western and eastern part of the imidazopyrimidinone core and combinations thereof, revealed compound 4a as a mGlu5 PAM with good in vitro potency and efficacy, acceptable drug metabolism and pharmacokinetic (DMPK) properties and in vivo efficacy in an amphetamine-based model of psychosis. However, the presence of CNS-mediated adverse effects in preclinical species precluded any further in vivo evaluation.

Keywords: Dihydroimidazopyrimidinone; Imidazopyrimidinone; Metabotropic glutamate receptor 5 (mGlu(5)); Positive allosteric modulator (PAM); Schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution strategy of dihydrothiazolopyridone 1 to other 5,6-bicyclic systems.
Figure 2
Figure 2
Dose-dependent effect and calculated terminal unbound brain of 4a on the reversal of amphetamine-induced hyperlocomotion in rats.
Scheme 1
Scheme 1
Reagents and conditions: (a) 1,3-dichloroacetone, AcOH, 110 °C, 16 h, 44%; (b) PhOH, K2CO3, ACN, 50 °C, 18 h, 53%; (c) LiOH, H2O/THF, 50 °C, 4 h, 98%; (d) Pd(OH)2/C, H2 atm, Et3N, AcOEt/MeOH, 50 °C, 45 psi, 16 h, in a Parr reactor, 92%; (e) R1X, CuI, N,N′-dimethylethylenediamine, K2CO3, toluene, 120 °C, 16 h, 22–73%.
Scheme 2
Scheme 2
Reagents and conditions: (a) for R1 = Alkyl: R1X, BuN4OH, DMF, rt, 2 h, 57–77% and for R1 = Aryl or heteroaryl: R1B(OH)2, Cu(OAc)2, TMEDA, MeOH/H2O, rt, 16 h, 48–65%; (b) 1,3-dichloroacetone, DMF, 150 °C, 30 min, microwave irradiation, 15–75%; (c) R2OH, K2CO3, ACN, 90 °C, 18 h, 58–95%; (d) I2, NaIO4, H2SO4, AcOH/water, 80 °C, 4 h, 84%; (e) MeB(OH)2, Pd(PPh3)4, K2CO3, 1,4-dioxane/DMF, 150 °C, 45 min, microwave irradiation, 72%.
Scheme 3
Scheme 3
Reagents and conditions: (a) Pd(OH)2/C, H2 atm, MeOH, 50 °C, 50 psi, 16 h, in a Parr reactor or Raney-Ni, 80 °C, full hydrogen mode, DMF/MeOH in an H-Cube reactor, 5–78%; (b) NBS, benzoyl peroxide, DCE, rt, 16 h, 35%; (c) MeB(OH)2, Pd(PPh3)4, K2CO3, 1,4-dioxane/DMF, 150 °C, 45 min, microwave irradiation, 56%; (d) NCS, DMF, 150 °C, 15–20 min, microwave irradiation, 27–55%.

Similar articles

Cited by

References

    1. Conn PJ, Lindsley CW, Jones CK. Trends Pharmacol. Sci. 2009;30:25. - PMC - PubMed
    1. Meltzer HY. Biol. Psychiatry. 1999;46:1321. - PubMed
    1. Kantrowitz J, Javitt DC. Curr. Opin. Psychiatry. 2012;25:96. - PMC - PubMed
    1. Moghaddam B, Javitt DC. Neuropsychopharmacology. 2012;37:4. - PMC - PubMed
    1. Schoepp DD, Jane DE, Monn JA. Neuropharmacology. 1999;38:1431. - PubMed

Publication types

MeSH terms